Disclaimer • Welcome • Why Alternatives? • Alternative Cancer Therapy Guides
Budwig Protocol • Causes • Detox • Downloads • Emotions • Energetics
Geopathic • Gerson • ”Greatest Hits” • Healing Cancer • History
Juicers • Light • Lothar Hirneise • Love • Healing & Mind
Nature Heals • “New Medicine” • Nutrition & Cancer
O2 & O3 • Preventing Cancer • Reference
Self-Healing Links • Spirituality
Supplements and Herbs
Thoughts on Healing
Testimonials
Sitemap
Write
us
•

www.healingcancernaturally.com
Why Choose Alternative Cancer Treatments?
page 14
 

On Conventional Medicine • On Modern Medicine • On Cancer Research
On Conventional Cancer Treatment • On Alternative Cancer Treatment
On Mammography •  On Cancer Diagnosing •  On Chemotherapy
On Cancer Business • On Nutrition & Cancer • On Mind Power
On Cancer Causes • On Drugs • On Nature & Self-Healing
Pain Medication Alternatives • On Avoidable Suffering
Possible Side Effects •  On Truth and Philosophy
On Cancer Statistics • On Healing of Cancer
p. 1 • p.2 • p.3 • p.4 • p.5 • p.6 • p. 7
p.8 • p.9 • p.10 • p.11 • p.12 • p.13
p.14 • p.15 • p.16 • p.17 • p.18
p. 19 • p. 20 • p. 21 • p. 22
On Loving and Healing
p. 23 • p. 24 • p. 25
p. 26 • p. 27
p.28 p.29
p. 30
•
 

It is in fact hard to find a single, common solid neoplasm [cancer] where management and expectation of cure has been markedly affected by animal research. Most human cancers differ from the artificially produced animal model....
Dr. Harrison in Clinical Oncology 1980;16:1-2

Welcome to page fourteen of “Why Choose Alternative Cancer Treatment?”. This series assembles a powerful sequence of incisive, outspoken (and often shocking) statements by cancer specialists, researchers and thinkers on subjects surrounding conventional and alternative cancer treatment. Numerous articles by medical researchers, personal advice & reports by former or current cancer patients, essays on avoidable suffering, the question why even very ill and suffering people - in spite of mainstream therapy failing to help them - may ridicule, reject, and attack medical alternatives in cancer treatment, and an introduction to the superior painless alternative to mammograms for women desirous of having their breasts screened, thermography, complete the picture...

Full introduction and complete list of Healing Cancer Naturally articles: Why Choose Alternative Cancer Treatment.

Page 14 and many more pages put the spotlight on...

Click here for the complete list of Healing Cancer Naturally articles on Cancer Research, Toxicity Testing & Animal Experimentation: an Unholy Union?

Contemporary Animal Experimentation
excerpted from A Critical Look at Animal Experimentation
published by © Medical Research Modernization Committee, 2002

Increasing numbers of scientists and clinicians are challenging animal experimentation on medical and scientific grounds.^1-3 Considerable evidence demonstrates that animal experimentation is inefficient and unreliable, while newly developed methodologies are more valid and less expensive than animal studies.

A. Selected Diseases

1. Cancer

In 1971 the National Cancer Act initiated a "War on Cancer" that many sponsors predicted would cure cancer by 1976. Instead, this multibillion dollar research program has proven to be a failure. The age-adjusted total cancer mortality rate climbed steadily for decades^31,32 until the early 1990s, when this rate started to fall slowly, due largely to reduced smoking.³³

In order to encourage continued support for cancer research--now exceeding two billion dollars annually--researchers and administrators have misled the public. In 1987, the U.S. General Accounting Office (GAO) found that the statistics of the National Cancer Institute (NCI) "artificially inflate the amount of 'true' progress," concluding that even simple five-year survival statistics were misused.³⁴ For one thing, the NCI termed five-year survival a "cure" even if the patient died of the cancer after the five-year period. Also, by ignoring well known statistical biases, the NCI falsely suggested advances had been made in the therapy of certain cancers.³⁴ Commenting on the research program's discouraging results, epidemiologist John Bailar III has stated, "The more promising areas are in cancer prevention."³¹

Why hasn't progress against cancer been commensurate with the effort (and money) invested? One explanation is the unwarranted preoccupation with animal research. Crucial genetic,³⁵ molecular,³⁶ immunologic,³⁷ and cellular³⁸ differences between humans and other animals have prevented animal models from serving as effective means by which to seek a cancer cure. Cancer researcher Jerome Leavitt has explained that human cancer "may have critical mechanical differences which may in turn require different, uniquely human approaches to cancer eradication."³⁶

2. AIDS

Despite extensive use, animal models have not contributed significantly to AIDS research. While monkeys, rabbits, and mice born with severe combined immunodeficiency can be infected with HIV, none develops the human AIDS syndrome.³⁹ Of over 100 chimpanzees infected with HIV over a ten year period, only a few have become sick.⁴⁰ Even AIDS researchers acknowledge that chimpanzees, as members of an endangered species who rarely develop an AIDS-like syndrome, are unlikely to prove useful as animal models for understanding the mechanism of infection or means of treatment.⁴¹ Other virus-induced immunodeficiency syndromes in non-human animals have been touted as valuable models of AIDS, but they differ markedly from AIDS in viral structure, disease symptoms, and disease progression.⁴² Animal researcher Michael Wyand, discussing anti-AIDS therapy, has acknowledged:

“Candidate antivirals have been screened using in vitro systems and those with acceptable safety profiles have gone directly into humans with little supportive efficacy data in any in vivo [animal] system. The reasons for this are complex but certainly include . . . the persistent view held by many that there is no predictive animal model for HIV infection in humans.”⁴³

AIDS researcher Margaret Johnston has concurred, "HIV/AIDS [animal] models have not yielded a clear correlate of immunity nor given consistent results on the potential efficacy of various vaccine approaches."⁴⁴

Human clinical investigation has isolated the AIDS virus (HIV), defined the disease's natural course, and identified risk factors.⁴⁵ In vitro (cell and tissue culture) research using human white blood cells has identified both the efficacy and toxicity of anti-AIDS medicines, including AZT,⁴⁶ 3TC,⁴⁷ and protease inhibitors.⁴⁸ Federal law, however, still mandates unnecessary animal toxicity testing.

4. Genetic Diseases

Scientists have located the genetic defects of many inherited diseases, including cystic fibrosis and familial breast cancer. Trying to "model" these diseases in animals, researchers widely use animals--mostly mice--with spontaneous or laboratory-induced genetic defects. However, genetic diseases reflect interactions between the defective gene and other genes and the environment. Consequently, nearly all such models have failed to reproduce the essential features of the analogous human conditions.⁶² For example, transgenic mice carrying the same defective gene as people with cystic fibrosis do not show the pancreatic blockages or lung infections that plague humans with the disease,⁶² because mice and humans have different metabolic pathways.⁶³

B. Toxicity Testing

Numerous standard animal toxicity tests have been widely criticized by clinicians and toxicologists. The lethal dose 50 (LD50), which determines how much of a drug, chemical, or household product is needed to kill 50 percent of a group of test animals, requires 60 to 100 animals (usually rats and mice), most of whom endure great suffering. Because of difficulties extrapolating the results to humans, the test is highly unreliable.⁶⁴ Also, since such variables as an animal's age, sex, weight, and strain can have a substantial effect on the results, laboratories often obtain widely disparate data with the same test substances.^65,66 In vitro tests could potentially completely replace the LD50.^66-68

The Draize eye irritancy test, in which unanesthetized rabbits have irritant substances applied to their eyes, yields results that are inherently unreliable in predicting human toxicity.⁶⁹ Humans and rabbits differ in the structure of their eyelids and corneas as well as their abilities to produce tears. Indeed, when comparing rabbit to human data on duration of eye inflammation after exposure to 14 household products, they differed by a factor of 18 to 250.⁷⁰ A battery of in vitro tests would be less expensive and likely more accurate than the Draize test.^65,71

Animal tests for cancer-causing substances, generally involving rodents, are also notoriously unreliable. Science editor Philip Abelson has asked, "Are humans to be regarded as behaving biochemically like huge, obese, inbred, cancer-prone rodents?"⁷² Of course, humans are not. Of 19 known human oral carcinogens, only 7 caused cancer in nonhuman animals using the standard NCI protocol.⁷³ Even different rodent species produce conflicting results. When Lester Lave et al. compared rat and mouse carcinogenicity for 214 chemicals, they found a correlation of only 70 percent.⁷⁴ (Chance alone would yield a 50 percent correlation.) A combination of in vitro tests provides data that compare favorably with existing carcinogenicity databases and costs far less than animal tests.⁷⁵

Scientific Limitations of Animal Models

Animal studies can neither confirm nor refute hypotheses about human physiology or pathology; human clinical investigation is the only way such hypotheses can be tested. At best, animal experiments can suggest new hypotheses that might be relevant to humans.^80,81 But, there are countless other, often superior, ways to derive new hypotheses.^2,80

How valuable is vivisection? The Medical Research Modernization Committee's review of ten randomly chosen animal models of human diseases did not reveal any important contributions to human health.⁸² Although the artificially induced conditions in animals were given names analogous to the human diseases they were intended to simulate, they differed substantially from their human "counterparts" in both cause and clinical course. Also, the study found that treatments effective in animals tended to have poor efficacy or excessive side-effects in human patients.⁸² Indeed, when MRMC physicians evaluate specific animal-research projects, they consistently find them of little, if any, relevance to the understanding or treatment of human diseases.^83-89

MRMC's reviews have revealed that, because animal models differ from human diseases, researchers tend to investigate those aspects of the animal's condition that resemble features of the human disease, generally ignoring or discounting fundamental anatomical, physiological, and pathological differences. Because most disease processes have system-wide effects and involve many interacting factors, focusing on only one aspect of a disease belies the actual complexity of biological organisms.

In contrast to human clinical investigation, vivisection involves manipulations of artificially induced conditions. Furthermore, the highly unnatural laboratory environment invariably stresses the animals, and stress affects the entire organism by altering pulse, blood pressure, hormone levels, immunological activities, and myriad other functions.^90,91 Indeed, many laboratory "discoveries" reflect mere laboratory artifact.^9,92-98 For example, artifact from unnaturally induced strokes in animals has repeatedly misled researchers.⁹⁹ In the 1980s researchers reported 25 compounds that reduce ischemic-stroke damage in nonhuman animals, but none proved effective in humans.⁹⁶ Subsequently, agents showing efficacy in animals have been unhelpful or even hazardous for human patients.^100,101

Animal tests frequently mislead.¹⁰² Milrinone increased survival of rats with artificially induced heart failure, but humans taking this drug experienced a 30% increase in mortality.¹⁰³ Fialuridine appeared safe in animal tests, but it caused liver failure in 7 of 15 humans taking the drug, five of whom died and two required liver transplantation.¹⁰⁴ Animal studies failed to predict dangerous heart valve abnormalities in humans induced by the diet drugs fenfluramine and dexfenfluramine.¹⁰⁵ Similarly, tests in monkeys failed to predict side-effects (jaundice, blood-clotting disorder, kidney failure, and lung failure) that killed an 18-year-old gene therapy patient in September 1999.¹⁰⁶

The General Accounting Office reviewed 198 of 209 drugs marketed from 1976 to 1985 and found that 52% had "serious postapproval risks" not predicted by animal tests.¹⁰⁷ 56 of 548 drugs (10%) approved between 1975 and 1999 were removed from the market or needed one or more special warnings for possible serious or life-threatening side-effects.¹⁰⁸ Despite extensive animal testing, adverse drug reactions remain a leading cause of mortality in the United States, accounting for roughly 100,000 deaths per year.¹⁰⁹

In animal tests of saccharin's carcinogenicity, the weight-adjusted daily saccharin dose given to rats was equivalent to a human's consuming about 1,100 cans of saccharin-containing soda. Such massive dosing itself can result in cancers, regardless of a compound's actual carcinogenicity at typical human exposure levels.⁹⁵ Extrapolating such data to humans is further complicated by the observation that saccharin-induced bladder cancers occurred only in male rats. It was later found that male rats possess a protein in greater quantity than female rats (and lacking in humans) that interacted with saccharin to form irritating crystals in the male rats' bladders, causing cancer. The fact that some rats developed cancers did not (and cannot) clarify whether or not saccharin causes cancer in humans.¹¹⁰

Scientists recognize that, just within humans, gender, ethnicity, age, and health can profoundly influence drug effects.^111,112 Obviously, extrapolating data between species is much more hazardous than within species. Consequently, animal studies are reliable at only the crudest levels—such as the ability of strong acids to damage eyes. However, such effects can be assessed easily with in vitro systems. For more subtle effects, animal models are unreliable.¹¹³

Animal Research Risks

In addition to squandering scarce resources and providing misleading results, vivisection poses real risks to humans. The mindset that scientific knowledge justifies (and may require) harming innocent individuals endangers all who are vulnerable. Even after Nazi and Japanese experiments on prisoners horrified the world, American researchers denied African-American men syphilis treatment in order to assess the disease's natural progression,¹¹⁴ injected cancer cells into nursing home patients,¹¹⁴ subjected unwitting patients to dangerous radiation experiments,¹¹⁵ and, despite no chance of success, transplanted nonhuman primate and porcine organs into children, chronically ill, and impoverished people.¹¹⁶ Psychiatrist Robert Jay Lifton argues that this "science at any cost" mentality may have provided medical justification for the Holocaust.¹¹⁷

Furthermore, through animal research, humans have been exposed to a wide variety of deadly nonhuman primate viruses. About 16 laboratory workers have been killed by the Marburg virus and other monkey viruses, and there have been two outbreaks of Ebola in American monkey colonies.^118-120 Polio vaccines grown on monkey kidney cells exposed millions of Americans to simian virus 40, which causes human cells to undergo malignant transformation in vitro and has been found in several human cancers.¹²¹ Ignoring the obvious public health hazards, researchers transplanted baboon bone marrow cells into an AIDS patient. The experiment was unsuccessful;¹²² moreover, a large number of baboon viruses, which the patient could spread to other people, may have accompanied the bone marrow. Indeed, vivisection may have started the AIDS epidemic. HIV-1, the principal AIDS virus, differs markedly from any virus found in nature, and there is evidence that it originated either through polio vaccine production using monkey tissues ^123,124 or through manufacture in American laboratories, where HIV-like viruses were being produced by cancer and biological weapons researchers in the early 1970s.¹²⁵

Failing to learn from the AIDS epidemic, many policy makers and industrial interests support animal-to-human organ transplants (from pigs and primates) known as xenotransplants. These have failed in the past, and are likely to continue to fail, because of tissue rejection, the impossibility of testing animal tissues for unknown pathogens, and the prohibitive expense.^126-128

Relatedly, the growing field of genetic engineering includes adding genetic material to animals’ cells to change the animals’ growth patterns or induce the animals to produce human proteins in their milk, food, or urine. This poses serious human risks, such as exposure to pathogens (viruses, prions, and other microorganisms)^129,130 or development of malignancies,^131,132 allergic reactions,¹³³ or antibiotic resistance.¹³⁴ These concerns contributed to the European Union’s ban on rBGH, a genetically engineered bovine growth hormone that increases cows’ milk production.¹³⁵
Compare Milk & the Cancer Connection II: Recombinant Bovine Growth Hormone (rBGH), Insulin-Like Growth Factor-1 (IGF-1) & Cancer Risk

The Importance of Clinical Research

Typically, medical discovery begins with a clinical observation,^8,9 which animal researchers then try to mimic with artificially induced animal conditions.⁶ These researchers tend to highlight animal data that accord with the previous clinical finding, while discounting or ignoring conflicting animal data (which are usually voluminous). Although animal research advocates routinely take credit for discoveries that actually occurred in a clinical context,⁶ many clinicians have recognized the primary role of human-based clinical research. Reviewing the history of hepatitis, physician Paul Beeson concluded:

“Progress in the understanding and management of human disease must begin, and end, with studies of man. . . Hepatitis, although an almost 'pure' example of progress by the study of man, is by no means unusual; in fact, it is more nearly the rule. To cite other examples: appendicitis, rheumatic fever, typhoid fever, ulcerative colitis and hyperparathyroidism.”¹⁰

Similarly, key discoveries in immunology,¹¹ anesthesiology,¹² first aid,¹³⁶ alcoholism ^60,137 and psychopharmacology^138-139 were based primarily on human clinical research and investigation. Furthermore, clinical research is the only means by which effective public health education and prevention programs can be developed and evaluated.

Non-Animal Methodologies

In science, there are always many ways to address a given question. Vivisection is generally less efficient and reliable than many non-animal methods, which include:

1. Epidemiology (Population Studies)

Medical research has always sought to identify the underlying causes of human disease in order to develop effective preventive and therapeutic measures. In contrast to artificial animal model conditions that generally differ in causes and mechanisms from human conditions, human population studies have been very fruitful. For example, the identification of risk factors for heart disease, so important for prevention techniques, derives from epidemiological studies.¹⁴⁰ Similarly, population studies have shown that passive smoking doubles the risk of developing lung cancer.¹⁴¹

Epidemiology's potential is illustrated by the growing field of molecular epidemiology. Researchers can analyze cellular and molecular characteristics of those suffering from cancer or birth defects, thereby elucidating the mechanisms and causes of DNA damage and yielding effective prevention and treatment approaches.¹⁴²

2. Patient Studies

The main source of medical knowledge has always been the direct study of human disease by closely monitoring human patients. For example, cardiologist Dean Ornish has demonstrated that a low-fat vegetarian diet, regular exercise, smoking cessation, and stress management can reverse heart disease.¹⁴³ Similarly, Caldwell Esselstyn has shown that lowering cholesterol levels with plant-based diets and medicines as needed arrests and often reverses heart disease.¹⁴⁴ Human cancer syndromes have played important roles in understanding more common forms of cancer.¹⁴⁵ Henry Heimlich has relied exclusively on human clinical investigation to develop techniques and operations that have saved thousands of lives, including the Heimlich Maneuver for choking and drowning victims, the Heimlich operation to replace the esophagus (throat tube), and the Heimlich Chest Drainage Valve.^136,146

Modern non-invasive imaging devices such as CAT, MRI, PET, and SPECT scans have revolutionized clinical investigation.^147-150 These devices permit the ongoing evaluation of human disease in living human patients, and have contributed greatly to medical knowledge.

3. Autopsies and Biopsies

The autopsy rate in the United States has been falling steadily, much to the dismay of clinical investigators who recognize the value of this traditional research tool.^151,152 Autopsies have been crucial to our current understanding of many diseases, such as heart disease,¹⁵¹ appendicitis,¹⁵¹ diabetes^153,154 and Alzheimer’s disease.⁸³ Although the usefulness of autopsies is generally limited to the disease's lethal stage, biopsies can provide information into other disease stages. Diagnostic needle and endoscopic biopsies often permit safe procurement of human tissues from living patients [but compare Biopsies can spread cancer]. For example, endoscopic biopsies have demonstrated that colon cancers derive from benign tumors called adenomas. In contrast, colon cancers in a leading animal model appear to lack this adenoma-to-carcinoma sequence.^155,156

4. Post-Marketing Surveillance

Because of computer technology, it is now possible to keep detailed and comprehensive records of drug side effects.¹⁵⁷ A central database with such information, derived from post-marketing surveillance, enables rapid identification of dangerous drugs.¹⁵⁸ Such a data system would also increase the likelihood that unexpected beneficial side effects of drugs would be recognized. Indeed, the anti-cancer properties of such medications as prednisone,¹⁵⁹ nitrogen mustard,¹⁶⁰ and actinomycin D;¹⁶¹ chlorpromazine's tranquilizing effect;¹⁶² and the mood-elevating effect of MAO-inhibitor¹⁶³ and tricyclic antidepressants¹⁶⁴ were all discovered through clinical observation of side effects.

5. Other Non-Animal Methods

In vitro cell and tissue cultures are powerful investigative tools. Between the mid-1950s and mid-1980s, the NCI screened 400,000 chemicals as possible anti-cancer agents, mostly on mice who had been given mouse leukemia.¹⁶⁵ The few compounds that were effective against mouse leukemia had little effect on the major human cancer killers.¹⁶⁶

More recently, researchers have favored grafting human cancers onto animals with impaired immune systems that do not reject grafts. However, few drugs found promising in these models have been clinically effective, and drugs with known effectiveness often fail to show efficacy with these models.¹⁶⁷ More promising and less costly is a screen of about 60 in vitro human cancer cell lines, a much less costly and more reliable alternative.¹⁶⁸ Similarly, in vitro tests using cells with human DNA can detect DNA damage much more readily than animal tests.¹⁶⁹

Regarding vaccines, in 1949 researchers discovered that vaccines made from human tissue cultures were more effective, safer, and less expensive than monkey tissue vaccines,^170,171 completely avoiding the serious danger of animal virus contamination.¹⁷² Likewise, many animal tests for viral vaccine safety have been replaced by far more sensitive and reliable cell culture techniques.^173,174

Antibodies have broad research and clinical applications. Researchers use millions of animals to produce antibodies by techniques that cause great suffering. Despite the ready availability of inexpensive in vitro methods, many researchers (who claim to use animals "only when necessary") don't bother to use the humane alternative.¹⁷⁵

Mathematical models using human clinical data are another source of information that is more reliable than data derived from animal studies.¹⁷⁶ Mathematical models use human clinical and epidemiological data to generate hypotheses about complex disease processes. For example, a mathematical model has indicated that there are two distinct types of breast cancer--one very malignant, the other much less so--that look alike under the microscope. This model suggests that the more malignant form requires early diagnosis and aggressive treatment, while excision is likely curative in the less malignant form.¹⁷⁷

Why Vivisection Persists

If animal experimentation is so flawed, why does it persist? There are several likely explanations.

Vivisection is easily published. In the "publish or perish" world of academic science, it requires little originality or insight to take an already well-defined animal model, change a variable or the species being used, and obtain "new" and "interesting" findings within a short period of time. In contrast, clinical research, while directly applicable to humans, is often more difficult and time-consuming. Also, the many species available and the nearly infinite possible manipulations offer researchers the opportunity to "prove" almost any theory that serves their economic, professional, or political needs. For example, researchers have "proven" in animals that cigarettes both do and do not cause cancer--depending on the funding source.^178,179

Vivisection is self-perpetuating. Scientists' salaries and professional status are often tied to grants, and a critical element of success in grant applications is proof of prior experience and expertise. Researchers trained in animal research techniques find it difficult or inconvenient to adopt new methods, such as tissue cultures.

Vivisection appears more "scientific" than clinical research. Researchers often assert that laboratory experiments are "controlled," because they can change one variable at a time. The control, however, is illusory. Any animal model differs in myriad ways from human physiology and pathology. In addition, the laboratory setting itself creates confounding variables--for example, stress and undesired or unrecognized pathology in the animals. Such variables can have system-wide effects, skew experimental results, and undermine extrapolation of findings to humans.

Vivisection is lucrative. Its traditionally respected place in modern medicine results in secure financial support, which is often an integral component of a university's budget. Many medical centers receive tens of millions of dollars annually in direct grants for animal research, and tens of millions more for overhead costs that are supposedly related to that research. Since these medical centers depend on this overhead for much of their administrative costs, construction, and building maintenance, they perpetuate vivisection by praising it in the media and to legislators.

Vivisection's morality is rarely questioned by researchers, who generally choose to dogmatically defend the practice rather than confront the obvious moral issues it raises.^180-183 Animal re-searchers' language betrays their efforts to avoid morality. For example, they "sacrifice" animals rather than kill them, and they may note animal "distress," but they rarely acknowledge pain or other suffering.¹⁸⁴ Young scientists quickly learn to adopt such a mindset from their superiors, as sociologist Arnold Arluke explains:

"One message--almost a warning--that newcomers got was that it was controversial or risky to admit to having ethical concerns, because to do so was tantamount to admitting that there really was something morally wrong with animal experimentation, thereby giving ‘ammunition to the enemy.’"¹⁸⁴

Animal researchers' ethical defense of the practice has been superficial and self-serving. Usually, they simply point to supposed human benefits and argue that the ends justify the means.^185,186 Often, they add that nonhuman animals are "inferior," lacking certain attributes compared to humans, such as intelligence, family structure, social bonding, communication skills, and altruism. However, numerous nonhuman animals--among them rats, pigs, dogs, monkeys, and great apes--reason and/or display altruism. There is accumulating evidence that many animals experience the same range of emotions as humans.^187-189 Chimpanzees and gorillas can be taught human sign language, and sign with one another even without humans present.^190,191

The general public, which cares about animal welfare, has been led to believe that animals rarely suffer in laboratories. Animal researchers often cite U.S. Department of Agriculture (USDA) statistics (derived from researchers themselves) that only 6 to 8 percent of animals used in vivisection experience pain unrelieved by anesthesia or analgesia.¹⁹² However, the 2002 Helms’ Amendment ensures that mice, rats, and birds, which constitute over 90% of all animals used in vivisection in the United States, receive absolutely no protection from the Animal Welfare Act.¹⁹³

Furthermore, evidence indicates that many animal researchers fail to acknowledge--or even perceive--animal pain and suffering. For example, sociologist Mary Phillips observed animal researchers kill rats in acute toxicity tests, induce cancer in rodents, subject animals to major surgery with no post-operative analgesia, and perform numerous other painful procedures without administering anesthesia or analgesia to the animals. Nevertheless, in their annual reports to the USDA, none of the re-searchers acknowledged that any animals had experienced unrelieved pain or distress. Phillips reported, "Over and over, researchers assured me that in their laboratories, animals were never hurt. . . 'Pain' meant the acute pain of surgery on conscious animals, and almost nothing else. . . [When I asked] about psychological or emotional suffering, many researchers were at a loss to answer."¹⁹⁴

The tens of millions of animals used and killed each year in American laboratories generally suffer enormously, often from fear and physical pain, nearly always from the deprivation inflicted by their confinement, which denies their most basic psychological and physical needs.

Conclusion

The value of animal experimentation has been grossly exaggerated by those with a vested economic interest in its preservation. Because animal experimentation focuses on artificially created pathology, involves confounding variables, and is undermined by differences in human and nonhuman anatomy, physiology, and pathology, it is an inherently unsound method to investigate human disease processes. The billions of dollars invested annually in animal research would be put to much more efficient, effective, and humane use if redirected to clinical and epidemiological research and public health programs.

Purchase Information:

This booklet costs .50 each, .30 in quantities of 10 or more, and can be obtained by contacting MRMC by e-mail (stkaufman at mindspring.com), or by contacting MRMC at:

Medical Research Modernization Committee
P.O. Box 201791
Cleveland, Ohio 44120
tel./fax 216-283-6702

References and Notes

1. The Physicians Committee for Responsible Medicine and the Medical Research Modernization Committee combined have over 4500 scientist and physician members, most of whom are highly critical of vivisection.
2. Barnard ND, Kaufman SR. Animal research is wasteful and misleading. Scientific American 1997;Feb:80-82.
3. Mukerjee M. Trends in animal research. Scientific American 1997;Feb:86- 93.
4. Loeb JM, Hendee WR, Smith SJ, Schwartz R. Human vs animal rights. In defense of animal research. Journal of the AMA 1989;262:2716-2720.
5. Botting JH, Morrison AD. Animal research is vital to medicine. Scientific American 1997;Feb:83-85.
6. Reines BP. On the locus of medical discovery. Journal of Medicine and Philosophy 1991;116:183-209.
7. Reines BP. On the role of clinical anomaly in Harvey's discovery of the mechanism of the pulse. Perspectives in Biology and Medicine 1990;34:128- 133.
8. McQuarrie I. The Experiments of Nature and Other Essays from the Porter Lectures. Lawrence, Kansas, University of Kansas Press, 1944.
9. Peller S. Quantitative Research in Human Biology and Medicine. Bristol, England, John Wright & Sons, 1967.
10. Beeson PB. The growth of knowledge about a disease: hepatitis. American Journal of Medicine 1979:67;366-370.
11. Good RA. Runestones in immunology. Journal of Immunology 1976; 117:1413-1428.
12. Good RA. Keystones. Journal of Clinical Investigation 1968;47:1466-1471. Beeson and Good have recently emphasized that they do not oppose animal experimentation, and they consider it important to medical progress. However, their own articles speak for themselves.
13. Greek CR, Greek JW. Sacred Cows and Golden Geese. New York, Continuum, 2000.
14. Greek CR, Greek JW. Specious Science. New York, Continuum, 2002.
15. Brecher R. The Consumers Union Report on Smoking and the Public Interest. Mount Vernon, Consumers Union, 1963.
16. Doll R, HillAB, The mortality of doctors in relation to their smoking habits: A preliminary report. British Medical Journal 1954;1:1451-1455.
17. Northrup E. Men, mice, and smoking, in Science Looks at Smoking. New York, Coward-McCann, 1957, p 133.
18. Enterline PE. Asbestos and cancer, in Gordis L (ed). Epidemiology & Health Risk Assessment. New York, Oxford Univ Pr, 1988.
19. Gardner MJ, Snee MP, Hall AJ, et al. Results of case-control study of leukaemia and lymphoma among young people near Sellafield nuclear plant in West Cumbria. British Medical Journal 1990;300:423-429.
20. Wald ML. Pioneer in radiation sees risk even in small doses. New York Times Dec 8, 1994, p A1.
21. Stewart A. Alternative sources of risk estimates for cancer effects of radiation. The Mount Sinai Journal of Medicine 1995;62:380-385.
22. Gould JM, Sternglass EJ. Nuclear fallout, low birthweight, and immune deficiency. International Journal of Health Science 1994;24:311-335.
23. Bross ID. Fifty Years of Folly and Fraud "In the Name of Science." Buffalo, Biomedical Metatechnology, 1994.
24. Ainley CC, Senapati A, Brown IM, et al. Is alcohol hepatotoxic in the baboon? Journal of Hepatology 1988;7:85-92.
25. Paul JR. History of Poliomyelitis. New Haven, YaleUniv. Press, 1971.
26. Sabin AB. Statement of Albert B. Sabin, M.D. Hearing before the Subcommittee on Hospitals and Health Care of the Committee on Veterans' Affairs of the House of Representatives, April 26, 1984, serial no 98-48.
27. Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissue. Science 1949;109:85-86.
28. Domingo RT, Fries C, Sawyer P, Wesolowski S. Peripheral arterial recon- struction. Transplantation of autologous veins. Transactions of the American Society of Artificial Internal Organs 1963;9:305-316.
29. Hume D. Experiences with Renal Homotransplantation in the Human Subject. Journal of Clinical Investigation 1955;34:327-381.
30. American Medical Association Council on Scientific Affairs. Animals in research. Journal of the AMA 1989;261:3602-3606.
31. Bailar JC III, Gornik HL. Cancer undefeated. New England Journal of Medicine 1997;336:1569-1574.
32. Beardsley T. A war not won. Scientific American 1994:270(1);130-138.
33. Jamal A, Thomas A, Murray T, Thun M. Cancer Statistics, 2002. CA Cancer Journal for Clinicians 2002;52:23-47.
34. US General Accounting Office. Cancer Patient Survival: What Progress has been Made? Washington, DC, General Accounting Office, 1987.
35. Dulbecco R. A turning point in cancer research: Sequencing the human genome. Science 1986;231:1055-1056.
36. Leavitt J. The case for understanding the molecular nature of cancer: Some recent findings and their implications. Medical News Sept 9, 1985.
37. BrossI. Crimes of Official Science. Buffalo, Biomedical Metatechnology, 1987.
38. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-467.
39. GardnerMB, Luciw PA. Animal Models of AIDS. FASEB Journal 1989;3:2593-2606.
40. Nath BM, Schumann KE, Boyer JD. The chimpanzee and other non- human-primate models in HIV-1 vaccine research. Trends in Microbiology 2000;8:426-431.
41. Stott J, Almond N. Assessing animal models of AIDS. Nature Medicine 1995;1:295-297.
42. Shortcomings of AIDS-Related Animal Experimentation. New York, Medical Research Modernization Committee, 1996.
43. Wyand MS. The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines. AIDS Research and Human Retroviruses 1992;8:349-356.
44. Johnston MI. The role of nonhuman primate models in AIDS vaccine development. Molecular Medicine Today 2000;6:267-270.
45. DeVita VT Jr., Hellman S, Rosenberg SA. AIDS Etiology, Diagnosis, Treatment, and Prevention, 3rd Edition. Philadelphia, JB Lippincott, 1992.
46. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'deoxythymidine (BS A509U). Proceedings of the National Academy of SciencesUSA 1985;82:7096-7100.
47. Soudeyns H, Yao X-J, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH 189), a novel heterocyclic nucleoside analog. Antimicrobial Agents and Chemotherapeutics 1991;35:1386-1390.
48. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990:248;358-361.
49. Giannelli MA. Three blind mice, see how they run: A critique of behavioral re- search with animals, in Fox MW, Mickley LD (eds). Advances in Animal Welfare Science 1985/86. WashingtonDC, Humane Society of the US, 1985, pp 109-164.
50. Cohen MJ. The irrelevance of animal experimentation in modern psychiatry and psychology, in Cohen MJ, Natelson N (eds) Facing the Challenge. AlexandriaVA, Concern for Helping Animals in Israel, 1991, pp 91-107.
51. Cohen MJ. Animal testing. Psychiatric News [letter]. Nov 20, 1987.
52. Bannister D. The fallacy of animal experimentation in psychology, in Sperlinger D (ed). Animals in Research. New York, John Wiley & Sons, 1981, pp 307-317.
    53. Bannister D. The myth of physiological psychology. Bulletin of the British Psychological Society 1968;21:229-231.
53. Shapiro K. Animal Models of Human Psychology: Critique of Science, Ethics and Policy. Seattle, Hogrefe & Huber, 1997.
54. Plous S. Attitudes towards the use of animals in psychological research and education: Results from a national survey of psychologists. American Psychologist 1996;51:1167-1180.
55. Bowlby J. Maternal care and mental health. Geneva, WHO Monograph Series, No. 2, 1952.
56. Spitz RA, Wolf KM. Anaclitic depression. Psychoanalytic Studies of the Child 1946;2:313-342.
57. Cohen MJ. A critique of the use of maternally deprived monkeys to study alcohol abuse. MRMC Report 1996;9(1):1-2.
58. Cohen MJ. A critique of maternal deprivation monkey experiments at The State University of New York Health Science Center. MRMC Report 1996;9(4):1-8.
59. Dole VP. On the relevance of animal models to alcoholism in humans. Alcoholism Clinical and Experimental Research 1986;10:361-363.
60. Kelly JA. Psychological research and the rights of animals: Disagreement with Miller [letter]. American Psychologist 1986;41:839-841.
61. Lee T. Gene Future. New York, Plenum Pr, 1993, p 177.
62. Clarke LL, Grubb BR, Gabriel SE, Smithes O, Koller BH, Boucher RC. Defective epithelial transport in a gene-targeted mouse model of cystic fibrosis. Science 1992;257:1125-1128.
63. Zbinden G, Flury-Roversi M. Significance of the LD50 test for the toxi- cological evaluation of chemical substances. Archives of Toxicology 1981:47;77-99.
64. Fano A. Lethal Laws: Animal Testing, Human Health and Environmental Policy. London, Zed Books, 1997, pp 157-159.
65. Stephens M. Replacing animal experiments, in Langley G (ed). Animal Experimentation: The Consensus Changes. New York, Chapman and Hall, 1989, pp 144-168.
66. Clemedson C, McFarlane-Abdulla E, Andersson M, et al.MEIC evaluation of acute systemic toxicity. Alternatives to Laboratory Animals 1996;24(suppl 1):273-311
68. Shrivastava R. In vitro tests in pharmacotoxicology. Alternatives to Laboratory Animals 1997;25:339-340.
69. Sharpe R. The Draize test--motivations for change. Food and Chemical Toxicology 1985;23:139-143.
70. Freeberg FE, Hooker DT, Griffith JF. Correlation of animal eye test data with human experience for household products: An update. Journal of Toxicology-Cutaneous & Ocular Toxicology 1986;5:115-123.
71. Langley G, Fisher G. New Perspectives in Cosmetic Toxicology: Non-animal Tier-Testing Strategies. London, International Fund for Animal Welfare, 1995.
72. Abelson PH. Diet and cancer in humans and rodents. Science 1992;255:141.
73. Salsburg D. The lifetime feeding study of mice and rats--an examination of its validity as a bioassay for human carcinogens. Fundamental and Applied Toxicology 1983;3:63-67.
74. Lave LB, Ennever FK, Rosenkranz HS, Omenn GS. Information value of the rodent bioassay. Nature 1988;336:631-633.
75. Worth AP, Balls M (eds). Alternative (Non-animal) Methods for Chemical Testing: Current Status and Future Prospects. ATLA 2002;30(suppl 1):83- 93.
76. Fawver AL, Branch CE, Trentham L, Robertson BT, Beckett SD. A comparison of interactive videodisc instruction with live animal laboratories. American Journal of Physiology 1990:259(Adv Physiol Educ 4);S11-S14.
77. Hepner LA. Animals in Education. Albuquerque, NM, Richmond Pub, 1994.
78. McGregor JC. The use of the placenta for microsurgical vascular practice. Journal of the RoyalCollege of Surgeons 1980;25:233-236.
79. Ota D, Loftin B, Saito T, Lea R, Keller J. Virtual reality in surgical education. Computers in Biology & Medicine 1995;25:127-137. See also www.meti.com.
80. LaFollette H, Shanks N. Animal models in biomedical research: Some epistemological worries. Public Affairs Quarterly 1992;7:113-130.
81. LaFollette H, Shanks N. Brute Science. New York, Routledge, 1997.
82. Kaufman SR, Reines BP, Casele H, Lawson L, Lurie J. An evaluation of ten randomly chosen animal models of human diseases. Perspectives on Animal Research 1989;1(Suppl):1-128.
83. Kaufman SR, Czarnecki T, Haralabatos I, Richardson M. Animal models of degenerative neurological diseases. Perspectives on Medical Research 1991;3:9-48.
84. Smith CD. A critique of brain wound research. Perspectives on Animal Research 1989;1:19-24.
85. Buyukmihci NC. Response to Dr. Blakemore's assertion that work involving nonhuman animals has led to significantly greater understanding and treatment of amblyopia. Perspectives on Animal Research 1989;1:57-62.
86. Cohen MJ, Black DN, Fouts RS, Dobbs FW. A critique of neurology experiments at Northwestern University. Perspectives on Medical Research 1993;4:22-28.
87. Kaufman SR. Animal models of spinal cord injury. Perspectives on Medical Research 1990;2:1-12.
88. Mack JD, Greenberg RA. Review of scoliosis research at the University of Michigan. Perspectives on Medical Research 1990;2:33-36.
89. Committee on Animal Models in Biomedical Research. Aping Science. New York, MRMC, 1995.
90. Barnard N, Hou S. Inherent stress: The tough life in lab routine. Lab Animal Sept 1988, pp 21-27.
91. Cotton P. Animals and science benefit from "replace, reduce, refine" effort. Journal of the AMA 1993;270:2906.
92. Hewitt HB. The use of animals in experimental cancer research, in Sperlinger D (ed). Animals in Research. New York, John Wiley & Sons, 1981.
93. Freedman DA, Zeisel H. From mouse to man: The quantitative assess- ment of cancer risks. Statistical Science 1988;3:3-28.
94. Smith CD. Head injury research at the University of Cincinnati. Perspectives on Animal Research 1989;1:9-18.
95. Ames BN, Gold LS. Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 1990;249:970-971.
96. Wiebers DO, Adams HP, Whisnant JP. Animal models of stroke: Are they relevant to human disease? Stroke 1990;21:1-3.
97. Habal MB. The influence of lip repair with and without soft-tissue under-mining on facial growth in beagles [discussion]. Plastic and Reconstructive Surgery 1988;82:756-759.
98. Fernandes D. Animal experimentation: Necessary or not? Cleft Palate Journal 1989;26:258.
99. Wiebers DO, Adams HP, Whisnant JP. Relevance of animal models to stroke [letter]. Stroke 1990;21:1091-1092.
100. Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347-354.
101. Sacco, RL, DeRosa JT, Haley Jr EC, et al. Glycine antagonist in neuro protection for patients with acute stroke. Journal of the American Medical Association 2001;285:1719-1728.
102. Sharpe R. Science on Trial. Sheffield, England, Awareness Pub,1994.
103. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure. New England Journal of Medicine 1991;325:1468-1475.
104. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine 1995;333:1099-1105.
105. Kolata G. 2 top diet drugs are recalled amid reports of heart defects. New York Times Sept 16, 1997, p A1.
106. Stolberg SG. New information on gene patient's death fails to resolve mystery. New York Times, December 2, 1999.
107. General Accounting Office. FDA Drug Review: Postapproval Risks 1976-1985. Washington, DC, GAO, 1990.
108. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. Journal of the American Medical Association 2002;287:2215-2220.
109. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. Journal of the American Medical Association 1998;279:1200-1205.
110. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science, 1990;249: 1007-1011.
111. Gear RW, Miaskowski C, GordonNC, Paul SM, Heller PH, Levine JD. Kappa-opioids produce significantly greater analgesia in women than in men. Nature Medicine 1996;2:1184-1185.
112. Berardesca E, Maibach IH. Racial differences in sodium lauryl sulphate induced cutaneous irritation: Black and White. Contact Dermatitis 1988;18:65-70.
113. Kaufman SR. Does vivisection pass the utilitarian test? Public Affairs Quarterly 1995;9:127-137.
114. Barber B. The ethics of experimentation with human subjects. Scientific American 1976;234(2):25-31.
115. Kiernan V. Radiation doctors abused trust in the name of science. New ScientistOct 14, 1995, p 8.
116. Annas GJ. Baby Fae: The "anything goes" school of human experimentation. Hastings Center Report 1985;15(1):15-17.
117. Lifton RJ. The Nazi Doctors. New York, Basic Books, 1986.
118. Preston R. The Hot Zone. New York, Random House, 1994.
119. Cohen MJ. Ebola Alice? TexasRepublic 1996;3(2):27-30.
120. McKenna MAJ. Monkey virus kills Yerkes researcher. Atlanta Journal- Constitution Dec 12, 1997.
121. Pennisi E. Monkey virus DNA found in rare human cancers. Science 1997;275:748-749.
122. Baboon cells fail to combat AIDS. Nature 1996;379:577.
123. Hooper. E. The River: A Journey to the Source of HIV and AIDS. Boston, Little, Brown & Co, 1999.
124. Reinhardt V, Roberts A. The African polio vaccine-acquired immune deficiency syndrome connection. Medical Hypotheses 1997;48:367-374.
125. Horowitz LG. Emerging Viruses: AIDS and Ebola. Rockport, Mass, Tetrahedron, 1996.
126. Allan JS. Xenotransplantation at a crossroads: Prevention versus progress. Nature Medicine 1996:2:18-21.
127. Fano A, Cohen MJ, Cramer M, Greek R, Kaufman SR. Of Pigs, Primates and Plagues: A Layperson's Guide to the Problems with Animal-to-Human Organ Transplants. New York, Medical Research Modernization Committee, 1997.
128. LeTissier P, Stoye JP, Takeuchi Y, Patience C, Weiss RA. Two sets of human-tropic pig retrovirus. Nature 1987;389:681-682.
129. Kimbrell A. The Human Body Shop. San Francisco, HarperCollins, 1994, pp 183-187.
130. Rhodes R. Deadly Feasts. New York, Simon & Schuster, 1997.
131. Epstein SS. Unlabeled milk from cows treated with biosynthetic growth hormones: A case of regulatory abdication. International Journal of Health Services 1996;26:173-185.
132. Epstein SS. A needless new risk of breast cancer. Los Angeles Times March 20, 1994.
133. Challcombe DN, Wheeler EE. Safety of milk from cows treated with bovine somatotropin. Lancet 1994;344:815-816.
134. Cummins R. An international boycott of genetically engineered foods. Pure Food Campaign, Washington, DC, March 4, 1997.
135. Leonard RE. Codex at the crossroads: Conflict on trade health. Nutrition Week 1995;25:4-5.
136. Heimlich HJ, Patrick EA. The Heimlich maneuver: Best technique for saving any choking victim's life. Postgraduate Medicine 1990;87:68-79.
137. Cohen MJ, Young C. "Alcoholic" Rats and Other Alcohol Research Using Animals. New York, NationalResearchInformationCenter, 1989.
138. Sitaram N, Gershon S. Animal models to clinical testing--promises and pitfalls. Progress in Neuropsychopharmacology Biology and Psychiatry 1983;7:227-228.
139. Davis JM. Antipsychotic drugs, in Kaplan HI, Sadock BJ (eds). Comprehensive Textbook of Psychiatry, Fourth Ed. Baltimore, William and Wilkins, 1985.
140. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. Circulation 1991;83:356-362.
141. Zaridze D, Maximovitch D, Zemlyanaya G, Aitakov ZN, Boffetta P. Exposure to environmental tobacco smoke and risk of lung cancer in non- smoking women from Moscow, Russia. International Journal of Cancer 1998;75:335-338.
142. Lower GM. Human carcinogenesis: A disciplinary perspective. Medical Hypotheses 1990;33:1-6.
143. Ornish D, for the Multicenter Lifestyle Demonstration Project Research Group. Avoiding revascularization with lifestyle changes: The multicenter lifestyle demonstration project. American Journal of Cardiology 1998;82:72T-76T.
144. Esselstyn Jr. CB. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease. American Journal of Cardiology 1999;84:339-341.
145. Zaridze D, Maximovitch D, Zemlyanaya G, Aitokov ZN, Boffetta P. Exposure to environmental tobacco smoke and risk of lung cancer in non-smoking women from Moscow, Russia. International Journal of Cancer 1998;75:335-338.
146. Heimlich HJ. Advantages and safety of clinical research, in Cohen M, Natelson N (eds). Facing the Challenge. Alexandria, VA, CHAI, 1990, pp 123-135.
147. Pechura CM, Martin JB (eds). Mapping the Brain and Its Functions. WashingtonDC, NationalAcademy Press, 1991.
148. Savoy RL. History and future directions of human brain mapping and functional neuroimaging. Acta Psychologica 2001;107:9-42.
149. Taylor-Robinson SD. Applications of magnetic resonance spectroscopy to chronic liver disease. Clinical Medicine 2001;1:54-60.
150. Schmermund A, Baumgart D, Erbel R. Coronary calcification by electron beam tomography: comparison with coronary risk factors and angiography. Journal of Cardiovascular Risk 2000;7:99-106.
151. Hill RB, Anderson RE. The Autopsy: Medical Practice and Public Policy. Boston, Butterworth, 1988.
152. Kaufman SR. Autopsy: A crucial component of human clinical investigation. Archives of Pathology and Laboratory Medicine 1996;120:767-770.
153. Opie EL. Disease of the Pancreas. Philadelphia, JB Lippincott, 1910.
154. Barron M. The relation of the islets of Langerhans to diabetes with spe- cial reference to cases of pancreatic lithiasis. Surgery, Gynecology and Obstetrics 1920;31:437-448.
155. Ahnen DJ. Are animal models of colon cancer relevant to human disease. Digestive Diseases & Sciences 1985;30(12 Suppl):103S-106S.
156. Pories SE, Ramchurren N, Summerhayes I, Steele G. Animal models for colon carcinogenesis. Archives of Surgery 1993;128:647-653.
157. Lasagna L (ed). Postmarketing Surveillance of Multisource Drugs. Boston, Center for the Study of Drug Development, 1986.
158. van Boxtel CJ, Wang G. Some observations on pharmacoepidemiology in Europe. Netherlands Journal of Medicine 1997;51:205-212.
159. Pearson OH, Eliel LP, Rawson RW, et al. ACTH- and cortisone-induced regression of lymphoid tumors in man. Cancer 1949;2:943-945.
160. Boesen E. Cytotoxic Drugs in the Treatment of Cancer. London, Edward Arnold, 1969, p 24.
161. Coley WB. A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas. The Post-Graduate 1893;8:278-286.
162. Caldwell A. Origins of Psychopharmacology: From CPZ to LSD. Springfield, Charles C Thomas, 1970.
163. Lehmann HE, KlineNS. Clinical discoveries with antidepressant drugs, in Parnham MJ, Bruinvels J (eds). Discoveries in Pharmacology, Volume 1. New York, Elsevier, 1983, pp 209-221.
164. Sulser F, Mishra R. The discovery of tricyclic antidepressants and their mode of action, in Parnham MJ, Bruinvels J (eds). Discoveries in Pharmacology, Volume 1. New York, Elsevier, 1983, pp 233-247.
165. Stevens C. Statement before the House Subcommittee on Labor, Health, and Human Services, April 30, 1987.